Kefton-2

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558202

CAS#: 6041-00-5

Description: Kefton-2 is bioactive chemical.

Chemical Structure

img
Kefton-2
CAS# 6041-00-5
Instruction

Theoretical Analysis

MedKoo Cat#: 558202
Name: Kefton-2
CAS#: 6041-00-5
Chemical Formula: C31H40O2
Exact Mass: 444.30
Molecular Weight: 444.660
Elemental Analysis: C, 83.74; H, 9.07; O, 7.20

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Kefton2; Kefton-2; Kefton 2;

IUPAC/Chemical Name: 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-

InChi Key: DKHGMERMDICWDU-GHDNBGIDSA-N

InChi Code: InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+

SMILES Code: O=C1C(C)=C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)C(C2=C1C=CC=C2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 444.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Iwamoto J. Vitamin K₂ therapy for postmenopausal osteoporosis. Nutrients. 2014 May 16;6(5):1971-80. doi: 10.3390/nu6051971. Review. PubMed PMID: 24841104; PubMed Central PMCID: PMC4042573.

2: Inoue T, Dohara Y, Sugihara K, Fujisaki S, Nagatani Y. [Intravenous Kefton-2, a hemostatic, in oral surgery]. Shikai Tenbo. 1980 Nov;56(5):871-5. Japanese. PubMed PMID: 6942517.

3: Shearer MJ, Newman P. Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res. 2014 Mar;55(3):345-62. doi: 10.1194/jlr.R045559. Epub 2014 Jan 31. Review. PubMed PMID: 24489112; PubMed Central PMCID: PMC3934721.

4: Jiang Y, Zhang ZL, Zhang ZL, Zhu HM, Wu YY, Cheng Q, Wu FL, Xing XP, Liu JL, Yu W, Meng XW. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clin Interv Aging. 2014;9:121-7. doi: 10.2147/CIA.S54107. Epub 2014 Jan 8. PubMed PMID: 24426779; PubMed Central PMCID: PMC3890406.

5: Avior Y, Levy G, Zimerman M, Kitsberg D, Schwartz R, Sadeh R, Moussaieff A, Cohen M, Itskovitz-Eldor J, Nahmias Y. Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes. Hepatology. 2015 Jul;62(1):265-78. doi: 10.1002/hep.27803. Epub 2015 Apr 22. PubMed PMID: 25808545.

6: Shikano K, Kaneko K, Kawazoe M, Kaburaki M, Hasunuma T, Kawai S. Efficacy of Vitamin K2 for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases. Intern Med. 2016;55(15):1997-2003. doi: 10.2169/internalmedicine.55.6230. Epub 2016 Aug 1. PubMed PMID: 27477405.

7: Okano T. A New Horizon in Vitamin K Research. Yakugaku Zasshi. 2016;136(8):1141-59. doi: 10.1248/yakushi.16-00014. Review. Japanese. PubMed PMID: 27477733.

8: Schumacher MM, Jun DJ, Jo Y, Seemann J, DeBose-Boyd RA. Geranylgeranyl-regulated transport of the prenyltransferase UBIAD1 between membranes of the ER and Golgi. J Lipid Res. 2016 Jul;57(7):1286-99. doi: 10.1194/jlr.M068759. Epub 2016 Apr 27. Erratum in: J Lipid Res. 2016 Aug;57(8):1599. PubMed PMID: 27121042; PubMed Central PMCID: PMC4918857.

9: Guralp O, Erel CT. Effects of vitamin K in postmenopausal women: mini review. Maturitas. 2014 Mar;77(3):294-9. doi: 10.1016/j.maturitas.2013.11.002. Epub 2013 Nov 27. Review. PubMed PMID: 24342502.

10: Gentili A, Cafolla A, Gasperi T, Bellante S, Caretti F, Curini R, Fernández VP. Rapid, high performance method for the determination of vitamin K(1), menaquinone-4 and vitamin K(1) 2,3-epoxide in human serum and plasma using liquid chromatography-hybrid quadrupole linear ion trap mass spectrometry. J Chromatogr A. 2014 Apr 18;1338:102-10. doi: 10.1016/j.chroma.2014.02.065. Epub 2014 Feb 28. PubMed PMID: 24630057.

11: Tsugawa N. [Clinical Pharmacokinetics of Active Vitamin D3 and its derivatives, and Vitamin K2(Menatetrenone).]. Clin Calcium. 2016;26(11):1547-1558. Japanese. PubMed PMID: 27777388.

12: Ferland G. Vitamin K and brain function. Semin Thromb Hemost. 2013 Nov;39(8):849-55. doi: 10.1055/s-0033-1357481. Epub 2013 Oct 9. Review. PubMed PMID: 24108469.

13: Iwamoto J, Sato Y. Menatetrenone for the treatment of osteoporosis. Expert Opin Pharmacother. 2013 Mar;14(4):449-58. doi: 10.1517/14656566.2013.763796. Epub 2013 Jan 25. Review. PubMed PMID: 23346882.

14: Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012 Nov 12;11:93. doi: 10.1186/1475-2891-11-93. PubMed PMID: 23140417; PubMed Central PMCID: PMC3502319.

15: Iwamoto J, Seki A, Sato Y, Matsumoto H. Vitamin K(2) improves renal function and increases femoral bone strength in rats with renal insufficiency. Calcif Tissue Int. 2012 Jan;90(1):50-9. doi: 10.1007/s00223-011-9548-3. Epub 2011 Nov 13. PubMed PMID: 22080166.

16: Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, Inoue K, Itoh K. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. Thromb Res. 2015 May;135(5):861-6. doi: 10.1016/j.thromres.2015.02.019. Epub 2015 Feb 27. PubMed PMID: 25747538.

17: Wu WJ, Kim MS, Ahn BY. The inhibitory effect of vitamin K on RANKL-induced osteoclast differentiation and bone resorption. Food Funct. 2015 Oct;6(10):3351-8. doi: 10.1039/c5fo00544b. PubMed PMID: 26267519.

18: Kiely M, Hodgins SJ, Merrigan BA, Tormey S, Kiely PA, O'Connor EM. Real-time cell analysis of the inhibitory effect of vitamin K2 on adhesion and proliferation of breast cancer cells. Nutr Res. 2015 Aug;35(8):736-43. doi: 10.1016/j.nutres.2015.05.014. Epub 2015 May 30. PubMed PMID: 26082424.

19: McCabe KM, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, Holden RM. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013 May;83(5):835-44. doi: 10.1038/ki.2012.477. Epub 2013 Jan 23. PubMed PMID: 23344475.

20: Wyskida K, Żak-Gołąb A, Łabuzek K, Suchy D, Ficek R, Pośpiech K, Olszanecka-Glinianowicz M, Okopień B, Więcek A, Chudek J. Daily intake and serum concentration of menaquinone-4 (MK-4) in haemodialysis patients with chronic kidney disease. Clin Biochem. 2015 Dec;48(18):1246-51. doi: 10.1016/j.clinbiochem.2015.08.011. Epub 2015 Aug 15. PubMed PMID: 26282719.